Novo Nordisk launches NovoCare rivaling Eli Lilly’s LillyDirect

by
Contributor since / Followers
4 weeks ago
Two packages of 5 dosing pens each of a fictitious Semiglutin drug used for weight loss (antidiabetic medication or anti-obesity medication) on a blue transparent background. Fictitious package design

aprott/iStock via Getty Images

Rivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk (NVO) on Wednesday launched NovoCare Pharmacy to offer the company’s weight loss drugs for cash-paying consumers.

Through NovoCare, the company will offer its obesity medicine

Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *